Skip to main content
. 2022 Mar 13;2(6):2100124. doi: 10.1002/smsc.202100124

Figure 4.

Figure 4

The antiviral activity of Oridonin against SARS‐CoV‐2. a) The relative copies of viral RNA present in the supernatant at 48 h postinfection determined by real‐time quantitative PCR analysis after Oridonin treatment; GC376 was used as a positive control. Unpaired t‐tests were used to compare the relative viral RNA copies incubated with inhibitor versus the DMSO control (n = 3 independent replicates; p = 0.0031 and 0.0137 for 1.56 μm GC376 and 3.13 μm Oridonin, respectively; not significant p > 0.05, * p < 0.05, and ** p < 0.01). b) The inhibitory effect of Oridonin and GC376 treatment on SARS‐CoV‐2 replication. GC376 was used as a positive control.